I started off as a pathologist at Boehringer-Ingelheim in Germany.
Stefan Platz
Head of Toxicology, Non-Clinical Safety Global Head, Early Safety, Roche
I started off as a pathologist at Boehringer-Ingelheim in Germany. When I accepted the position as the head of Non-Clinical Safety in Palo Alto, CA, and moved from a classical German culture to Silicon Valley, I was amazed by the speed and the innovative culture around me. It was a very stimulating and interesting environment.
There is the expectation that younger leaders will come into the industry with a more creative mindset, open to new ideas and concepts of innovation. There are many exciting innovations likely to occur in the coming years, especially in the development of new technologies. One very interesting emerging technology is the field of small interfering RNA (siRNA). Compared to small molecules, siRNA offers the opportunity to be more selective and potent against a well-defined target.
I sought a career to find cures to diseases and help patients around the world. It was and still is enticing to be part of a team that develops drugs that one day will save lives.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.